Entero Healthcare Solutions Limited has informed the Exchange about Acquisition
ENTERO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts less than Nifty Microcap 250 and 2.4 pts less than its Retailing peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Entero Healthcare Solutions reported strong FY26 consolidated profit of Rs 1,458.40 million, up 35.7% from Rs 1,074.34 million in FY25, despite consolidated revenue growth to Rs 65,912.12 million from Rs 50,957.80 million. The company approved acquisition of Vishal Surgicals and Vishal Surgicals & Medicals (a partnership firm) through its subsidiary Sai Pharma Distributors Private Limited via Slump Sale/Business Transfer Agreement. During FY26, Entero completed multiple acquisitions including Ramson Medical, S K Pharma, Well Wisher Pharma, and others. Three independent directors were reappointed for second term. The 8th AGM is scheduled for August 19, 2026.
The 36% YoY rise in consolidated profit is positive for shareholders. The new acquisition via subsidiary expands the pharma distribution network. Multiple acquisitions during the year drove the revenue growth but also increased borrowings to Rs 5,666.83 million on consolidated basis.